From OpenWetWare
Jump to navigationJump to search

Alzheimers treatment by preventing dimerization using protein inhibitors Alzheimers disease is caused by the accumulation of amyloids, or protein fibrils caused by the aggregation of beta-sheets that accumulate as plaques. A strategy for inhibiting aggregation of amyloid beta fibrils is using peptide-baed inhibitors focused on the internal sequence (16-22) KLVFFAE, identified to be responsible for self-association and aggregation. Previous inhibitors used strained proline, N-methylated amino acids, soluble peptides, D-amino acids, and added targeting sequences. A designed OR2 peptide was found to be a good inhibitor, but it required additional modifications to be a viable therapy: Arg at N and C to prevent aggregation of OR2 itself, and making it a "retro-inverso" version with opposite C->N directionality and some amino acids replaced with the D-isomer.

Currently, we are looking into previous research that's studying:

- other forms of treatment/prevention of aggregation of amyloids (ie. inhibition? active breaking up of aggregates? etc)

- other forms of inhibition for Alzheimers treatment (ie. protein, chemical inhibitors)

- protein inhibitors for other amyloid-based diseases